Skip to main content

Articles

Page 7 of 25

  1. Studies regarding the lipid-cognition relationship have increasingly gained popularity but have generated much mixed results. To date, few studies have focused on the difference between sexes.

    Authors: Lili Liu, Chen Zhang, Xiaozhen Lv, Xuefeng Lai, Lu Xu, Jingnan Feng, Yongfeng Song, Shengfeng Wang and Siyan Zhan
    Citation: Alzheimer's Research & Therapy 2020 12:164
  2. MicroRNAs (miRNAs) are noncoding RNAs that are highly relevant as disease biomarkers. Several studies that explored the role of miRNAs in Alzheimer’s disease (AD) demonstrated their usefulness in clinical iden...

    Authors: F. Dakterzada, A. Targa, I. D. Benítez, L. Romero-ElKhayat, D. de Gonzalo-Calvo, G. Torres, A. Moncusí-Moix, R. Huerto, M. Sánchez-de-la-Torre, F. Barbé and G. Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2020 12:163
  3. Blood-based amyloid biomarkers may provide a non-invasive, cost-effective and scalable manner for detecting cerebral amyloidosis in early disease stages.

    Authors: Steffi De Meyer, Jolien M. Schaeverbeke, Inge M. W. Verberk, Benjamin Gille, Maxim De Schaepdryver, Emma S. Luckett, Silvy Gabel, Rose Bruffaerts, Kimberley Mauroo, Elisabeth H. Thijssen, Erik Stoops, Hugo M. Vanderstichele, Charlotte E. Teunissen, Rik Vandenberghe and Koen Poesen
    Citation: Alzheimer's Research & Therapy 2020 12:162
  4. The retina and brain share many neuronal and vasculature characteristics. We investigated the retinal microvasculature in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) using optical coherence to...

    Authors: Jacqueline Chua, Qinglan Hu, Mengyuan Ke, Bingyao Tan, Jimmy Hong, Xinwen Yao, Saima Hilal, Narayanaswamy Venketasubramanian, Gerhard Garhöfer, Carol Y. Cheung, Tien Yin Wong, Christopher Li-Hsian Chen and Leopold Schmetterer
    Citation: Alzheimer's Research & Therapy 2020 12:161
  5. Understanding the earliest pathophysiological changes of Alzheimer’s disease (AD) may aid in the search for timely diagnostic biomarkers and effective disease-modifying therapies. The p53 protein is mostly kno...

    Authors: Giulia Abate, Giovanni B. Frisoni, Jean-Christophe Bourdon, Simona Piccirella, Maurizio Memo and Daniela Uberti
    Citation: Alzheimer's Research & Therapy 2020 12:160
  6. Alpha-synuclein (α-Syn) aggregation is the primary characteristic of synucleinopathies including Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Immunotherapy targe...

    Authors: Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare and James A. R. Nicoll
    Citation: Alzheimer's Research & Therapy 2020 12:159
  7. Previous studies have shown that copy number variation (CNV) in the alpha (α)-amylase gene (AMY1A) is associated with body mass index, insulin resistance, and blood glucose levels, factors also shown to increase ...

    Authors: Elin Byman, Katarina Nägga, Anna-Märta Gustavsson, Johanna Andersson-Assarsson, Oskar Hansson, Emily Sonestedt and Malin Wennström
    Citation: Alzheimer's Research & Therapy 2020 12:158
  8. To investigate the association between pineal gland volume and symptoms of rapid eye movement (REM) sleep behavior disorder (RBD) in Alzheimer’s disease (AD) patients without any feature of dementia with Lewy ...

    Authors: Jeongbin Park, Seung Wan Suh, Grace Eun Kim, Subin Lee, Jun Sung Kim, Hye Sung Kim, Seonjeong Byun, Jong Bin Bae, Jae Hyoung Kim, Sang Eun Kim, Ji Won Han and Ki Woong Kim
    Citation: Alzheimer's Research & Therapy 2020 12:157
  9. Although the heritability of sporadic Alzheimer’s disease (AD) is estimated to be 60–80%, addressing the genetic contribution to AD risk still remains elusive. More specifically, it remains unclear whether gen...

    Authors: Jieun Seo, Min Soo Byun, Dahyun Yi, Jun Ho Lee, So Yeon Jeon, Seong A. Shin, Yu Kyeong Kim, Koung Mi Kang, Chul-Ho Sohn, Gijung Jung, Jong-Chan Park, Sun-Ho Han, Jayoung Byun, Inhee Mook-Jung, Dong Young Lee and Murim Choi
    Citation: Alzheimer's Research & Therapy 2020 12:156
  10. Amyloid-β (Aβ) PET is an established predictor of conversion from mild cognitive impairment (MCI) to Alzheimer’s dementia (AD). We compared three PET (including an approach based on voxel-wise Cox regression) ...

    Authors: Arnd Sörensen, Ganna Blazhenets, Florian Schiller, Philipp Tobias Meyer and Lars Frings
    Citation: Alzheimer's Research & Therapy 2020 12:155
  11. Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer’s disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is es...

    Authors: Filipa Landeiro, Seher Mughal, Katie Walsh, Elsbeth Nye, Jasmine Morton, Harriet Williams, Isaac Ghinai, Yovanna Castro, José Leal, Nia Roberts, Helena Wace, Ron Handels, Pascal Lecomte, Anders Gustavsson, Emilse Roncancio-Diaz, Mark Belger…
    Citation: Alzheimer's Research & Therapy 2020 12:154
  12. The underlying disease mechanism of neuropsychiatric symptoms (NPS) in dementia remains unclear. Cerebrospinal fluid (CSF) biomarkers for synaptic and axonal degeneration may provide novel neuropathological in...

    Authors: Victor Bloniecki, Henrik Zetterberg, Dag Aarsland, Patrizia Vannini, Hlin Kvartsberg, Bengt Winblad, Kaj Blennow and Yvonne Freund-Levi
    Citation: Alzheimer's Research & Therapy 2020 12:153
  13. A consensus protocol for genetic counselling and testing of familial dementia, the Italian Dominantly Inherited Alzheimer’s and Frontotemporal Network (IT-DIAfN) protocol, has been developed in Italy by a netw...

    Authors: Anna Mega, Samantha Galluzzi, Cristian Bonvicini, Silvia Fostinelli, Massimo Gennarelli, Cristina Geroldi, Orazio Zanetti, Luisa Benussi, Emilio Di Maria and Giovanni B. Frisoni
    Citation: Alzheimer's Research & Therapy 2020 12:152
  14. TREM2 is a microglial cell surface receptor, with risk mutations linked to Alzheimer’s disease (AD), including R47H. TREM2 signalling via SYK aids phagocytosis, chemotaxis, survival, and changes to microglial act...

    Authors: Hazel Hall-Roberts, Devika Agarwal, Juliane Obst, Thomas B. Smith, Jimena Monzón-Sandoval, Elena Di Daniel, Caleb Webber, William S. James, Emma Mead, John B. Davis and Sally A. Cowley
    Citation: Alzheimer's Research & Therapy 2020 12:151
  15. In recent years, mechanistic, epidemiologic, and interventional studies have indicated beneficial effects of omega-3 polyunsaturated fatty acids (n-3 PUFA) against brain aging and age-related cognitive decline...

    Authors: Debora Cutuli, Eugenia Landolfo, Annalisa Nobili, Paola De Bartolo, Stefano Sacchetti, Doriana Chirico, Federica Marini, Luisa Pieroni, Maurizio Ronci, Marcello D’Amelio, Francesca Romana D’Amato, Stefano Farioli-Vecchioli and Laura Petrosini
    Citation: Alzheimer's Research & Therapy 2020 12:150
  16. Amyloid β (Aβ)-directed immunotherapy has shown promising results in preclinical and early clinical Alzheimer’s disease (AD) trials, but successful translation to late clinics has failed so far. Compelling evi...

    Authors: Kathrin Gnoth, Anke Piechotta, Martin Kleinschmidt, Sandra Konrath, Mathias Schenk, Nadine Taudte, Daniel Ramsbeck, Vera Rieckmann, Stefanie Geissler, Rico Eichentopf, Susan Barendrecht, Maike Hartlage-Rübsamen, Hans-Ulrich Demuth, Steffen Roßner, Holger Cynis, Jens-Ulrich Rahfeld…
    Citation: Alzheimer's Research & Therapy 2020 12:149
  17. We previously found temporoparietal-predominant atrophy patterns in the behavioral variant of Alzheimer’s disease (bvAD), with relative sparing of frontal regions. Here, we aimed to understand the clinico-anat...

    Authors: Ellen H. Singleton, Yolande A. L. Pijnenburg, Carole H. Sudre, Colin Groot, Elena Kochova, Frederik Barkhof, Renaud La Joie, Howard J. Rosen, William W. Seeley, Bruce Miller, M. Jorge Cardoso, Janne Papma, Philip Scheltens, Gil D. Rabinovici and Rik Ossenkoppele
    Citation: Alzheimer's Research & Therapy 2020 12:148
  18. Plasma neurofilament light (NFL) and total Tau (t-Tau) proteins are candidate biomarkers for early stages of Alzheimer’s disease (AD). The impact of biological factors on their plasma concentrations in individ...

    Authors: Filippo Baldacci, Simone Lista, Maria Laura Manca, Patrizia A. Chiesa, Enrica Cavedo, Pablo Lemercier, Henrik Zetterberg, Kaj Blennow, Marie-Odile Habert, Marie Claude Potier, Bruno Dubois, Andrea Vergallo and Harald Hampel
    Citation: Alzheimer's Research & Therapy 2020 12:147
  19. Alzheimer’s disease (AD) is characterized by progressive memory loss and cognitive impairment. The aggregation of amyloid β (Aβ) and hyperphosphorylated tau protein are two major pathological features of AD. N...

    Authors: Ping Gong, Yan-qing Chen, Ai-hua Lin, Hai-bo Zhang, Yan Zhang, Richard D. Ye and Yang Yu
    Citation: Alzheimer's Research & Therapy 2020 12:146
  20. Physical activity has been suggested to prevent the conversion of mild cognitive impairment (MCI) to dementia in patients. We investigated the association between the continuance and regularity of physical act...

    Authors: Yeo Jin Kim, Kyung-Do Han, Min Seok Baek, Hanna Cho, Eun Joo Lee and Chul Hyoung Lyoo
    Citation: Alzheimer's Research & Therapy 2020 12:136
  21. Mild cognitive impairment (MCI) is a precursor to Alzheimer’s disease (AD), but not all MCI patients develop AD. Biomarkers for early detection of individuals at high risk for MCI-to-AD conversion are urgently...

    Authors: Daichi Shigemizu, Shintaro Akiyama, Sayuri Higaki, Taiki Sugimoto, Takashi Sakurai, Keith A. Boroevich, Alok Sharma, Tatsuhiko Tsunoda, Takahiro Ochiya, Shumpei Niida and Kouichi Ozaki
    Citation: Alzheimer's Research & Therapy 2020 12:145
  22. The eye offers potential for the diagnosis of Alzheimer’s disease (AD) with retinal imaging techniques being explored to quantify amyloid accumulation and aspects of neurodegeneration. To assess these changes,...

    Authors: Sophie Lemmens, Toon Van Craenendonck, Jan Van Eijgen, Lies De Groef, Rose Bruffaerts, Danilo Andrade de Jesus, Wouter Charle, Murali Jayapala, Gordana Sunaric-Mégevand, Arnout Standaert, Jan Theunis, Karel Van Keer, Mathieu Vandenbulcke, Lieve Moons, Rik Vandenberghe, Patrick De Boever…
    Citation: Alzheimer's Research & Therapy 2020 12:144
  23. The Amyloid/Tau/Neurodegeneration (ATN) framework has been proposed as a means of evidencing the biological state of Alzheimer’s disease (AD). Predicting ATN status in pre-dementia individuals therefore provid...

    Authors: Catherine M. Calvin, Casper de Boer, Vanessa Raymont, John Gallacher and Ivan Koychev
    Citation: Alzheimer's Research & Therapy 2020 12:143
  24. Given the growing older population worldwide, and the associated increase in age-related diseases, such as Alzheimer’s disease (AD), investigating non-invasive methods to ameliorate or even prevent cognitive d...

    Authors: Friederike Thams, Anna Kuzmina, Malte Backhaus, Shu-Chen Li, Ulrike Grittner, Daria Antonenko and Agnes Flöel
    Citation: Alzheimer's Research & Therapy 2020 12:142
  25. Possession of the ε4 allele of apolipoprotein E (APOE) is the primary genetic risk factor for the sporadic form of Alzheimer’s disease (AD). While researchers have extensively characterized the impact that APOE ε...

    Authors: Sheina Emrani, Hirra A. Arain, Cassandra DeMarshall and Tal Nuriel
    Citation: Alzheimer's Research & Therapy 2020 12:141
  26. The disintegrin metalloproteinase 10 (ADAM10) is the main α-secretase acting in the non-amyloidogenic processing of APP. Some ADAM10 gene variants have been associated with higher susceptibility to develop late-o...

    Authors: Pablo Agüero, María José Sainz, María-Salud García-Ayllón, Javier Sáez-Valero, Raquel Téllez, Rosa Guerrero-López, Julián Pérez-Pérez, Adriano Jiménez-Escrig and Estrella Gómez-Tortosa
    Citation: Alzheimer's Research & Therapy 2020 12:139
  27. Impairment in daily functioning is a clinical hallmark of dementia. Difficulties with “instrumental activities of daily living” (IADL) seem to increase gradually over the course of Alzheimer’s disease (AD), be...

    Authors: Mark A. Dubbelman, Roos J. Jutten, Sarah E. Tomaszewski Farias, Rebecca E. Amariglio, Rachel F. Buckley, Pieter Jelle Visser, Dorene M. Rentz, Keith A. Johnson, Michael J. Properzi, Aaron Schultz, Nancy Donovan, Jennifer R. Gatchell, Charlotte E. Teunissen, Bart N. M. Van Berckel, Wiesje M. Van der Flier, Reisa A. Sperling…
    Citation: Alzheimer's Research & Therapy 2020 12:138
  28. Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson’s disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Sympt...

    Authors: Jennifer G. Goldman, Leah K. Forsberg, Bradley F. Boeve, Melissa J. Armstrong, David J. Irwin, Tanis J. Ferman, Doug Galasko, James E. Galvin, Daniel Kaufer, James Leverenz, Carol F. Lippa, Karen Marder, Victor Abler, Kevin Biglan, Michael Irizarry, Bill Keller…
    Citation: Alzheimer's Research & Therapy 2020 12:137
  29. The Multidomain Alzheimer Preventive Trial (MAPT) was designed to assess the efficacy of omega-3 fatty acid supplementation, multidomain intervention (MI), or a combination of both on cognition. Although the M...

    Authors: Julien Delrieu, Thierry Voisin, Laure Saint-Aubert, Isabelle Carrie, Christelle Cantet, Bruno Vellas, Pierre Payoux and Sandrine Andrieu
    Citation: Alzheimer's Research & Therapy 2020 12:134
  30. FDG-PET hypermetabolism can be observed in mild cognitive impairment (MCI), but the link to primary pathologies of Alzheimer’s diseases (AD) including amyloid and tau is unclear.

    Authors: Anna Rubinski, Nicolai Franzmeier, Julia Neitzel and Michael Ewers
    Citation: Alzheimer's Research & Therapy 2020 12:133
  31. Self-assembly of the amyloid-β (Aβ) peptide into aggregates, from small oligomers to amyloid fibrils, is fundamentally linked with Alzheimer’s disease (AD). However, it is clear that not all forms of Aβ are eq...

    Authors: Lorena De Mena, Michael A. Smith, Jason Martin, Katie L. Dunton, Carolina Ceballos-Diaz, Karen R. Jansen-West, Pedro E. Cruz, Kristy D. Dillon, Diego E. Rincon-Limas, Todd E. Golde, Brenda D. Moore and Yona Levites
    Citation: Alzheimer's Research & Therapy 2020 12:132
  32. Early identification of individuals at risk of dementia is mandatory to implement prevention strategies and design clinical trials that target early disease stages. Subjective cognitive decline (SCD) and neuro...

    Authors: Lena Sannemann, Ann-Katrin Schild, Slawek Altenstein, Claudia Bartels, Frederic Brosseron, Katharina Buerger, Nicoleta Carmen Cosma, Klaus Fliessbach, Silka Dawn Freiesleben, Wenzel Glanz, Michael T. Heneka, Daniel Janowitz, Ingo Kilimann, Xenia Kobeleva, Christoph Laske, Coraline D. Metzger…
    Citation: Alzheimer's Research & Therapy 2020 12:131
  33. β-Secretase1 (BACE1) protein concentrations and rates of enzyme activity, analyzed in human bodily fluids, are promising candidate biological markers for guidance in clinical trials investigating BACE1 inhibit...

    Authors: Harald Hampel, Simone Lista, Eugeen Vanmechelen, Henrik Zetterberg, Filippo Sean Giorgi, Alessandro Galgani, Kaj Blennow, Filippo Caraci, Brati Das, Riqiang Yan and Andrea Vergallo
    Citation: Alzheimer's Research & Therapy 2020 12:130
  34. Lack of awareness of cognitive decline (ACD) is common in late-stage Alzheimer’s disease (AD). Recent studies showed that ACD can also be reduced in the early stages.

    Authors: Federica Cacciamani, Luisa Sambati, Marion Houot, Marie-Odile Habert, Bruno Dubois and Stéphane Epelbaum
    Citation: Alzheimer's Research & Therapy 2020 12:129
  35. Cognition is closely associated with physical function. Although high brain amyloid-β (Aβ) deposition and neurofilament light chain (NfL) are associated with cognitive and gait speed decline, relationships of ...

    Authors: Lingxiao He, Philipe de Souto Barreto, Geetika Aggarwal, Andrew D. Nguyen, John E. Morley, Yan Li, Randall J. Bateman and Bruno Vellas
    Citation: Alzheimer's Research & Therapy 2020 12:128
  36. White matter hyperintensities (WMH) are very frequent in older adults and associated with worse cognitive performance. Little is known about the links between WMH and vascular risk factors, cortical β-amyloid ...

    Authors: Antoine Garnier-Crussard, Salma Bougacha, Miranka Wirth, Claire André, Marion Delarue, Brigitte Landeau, Florence Mézenge, Elizabeth Kuhn, Julie Gonneaud, Anne Chocat, Anne Quillard, Eglantine Ferrand-Devouge, Vincent de La Sayette, Denis Vivien, Pierre Krolak-Salmon and Gaël Chételat
    Citation: Alzheimer's Research & Therapy 2020 12:127
  37. Understanding the earliest manifestations of Alzheimer’s disease (AD) is key to realising disease-modifying treatments. Advances in neuroimaging and fluid biomarkers have improved our ability to identify AD pa...

    Authors: Antoinette O’Connor, Philip S. J. Weston, Ivanna M. Pavisic, Natalie S. Ryan, Jessica D. Collins, Kirsty Lu, Sebastian J. Crutch, Daniel C. Alexander, Nick C. Fox and Neil P. Oxtoby
    Citation: Alzheimer's Research & Therapy 2020 12:126
  38. Soluble beta-amyloid (Aβ) can be cleared from the brain through various mechanisms including enzymatic degradation, glial cell phagocytosis, transport across the blood-brain barrier, and glymphatic clearance. ...

    Authors: Weixi Feng, Yanli Zhang, Ze Wang, Hanrong Xu, Ting Wu, Charles Marshall, Junying Gao and Ming Xiao
    Citation: Alzheimer's Research & Therapy 2020 12:125
  39. Lysophosphatidic acids (LPAs) are bioactive signaling phospholipids that have been implicated in Alzheimer’s disease (AD). It is largely unknown whether LPAs are associated with AD pathology and progression fr...

    Authors: Shahzad Ahmad, Adelina Orellana, Isabelle Kohler, Lutz Frölich, Itziar de Rojas, Silvia Gil, Mercè Boada, Isabel Hernández, Lucrezia Hausner, Margot H. M. Bakker, Alfredo Cabrera-Socorro, Najaf Amin, Alfredo Ramírez, Agustín Ruiz, Thomas Hankemeier and Cornelia M. Van Duijn
    Citation: Alzheimer's Research & Therapy 2020 12:124
  40. Amyloid pathology, which is one of the characteristics of Alzheimer’s disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease...

    Authors: Sylvain Lehmann, Julien Dumurgier, Xavier Ayrignac, Cecilia Marelli, Daniel Alcolea, Juan Fortea Ormaechea, Eric Thouvenot, Constance Delaby, Christophe Hirtz, Jérôme Vialaret, Nelly Ginestet, Elodie Bouaziz-Amar, Jean-Louis Laplanche, Pierre Labauge, Claire Paquet, Alberto Lleo…
    Citation: Alzheimer's Research & Therapy 2020 12:123
  41. There has been ongoing research impetus to uncover novel blood-based diagnostic and prognostic biomarkers for Alzheimer’s disease (AD), vascular dementia (VaD), and related cerebrovascular disease (CEVD)-assoc...

    Authors: Xin Ying Chua, Yuek Ling Chai, Wee Siong Chew, Joyce R. Chong, Hui Li Ang, Ping Xiang, Kaddy Camara, Amy R. Howell, Federico Torta, Markus R. Wenk, Saima Hilal, Narayanaswamy Venketasubramanian, Christopher P. Chen, Deron R. Herr and Mitchell K. P. Lai
    Citation: Alzheimer's Research & Therapy 2020 12:122
  42. Cerebrospinal fluid (CSF) amyloid-beta (Aβ) 42/40 ratio, threonine-181-phosphorylated-tau (p-tau), and total-tau (t-tau) represent core biomarkers of Alzheimer disease (AD). The recent availability of automate...

    Authors: Giovanni Bellomo, Samuela Cataldi, Silvia Paciotti, Federico Paolini Paoletti, Davide Chiasserini and Lucilla Parnetti
    Citation: Alzheimer's Research & Therapy 2020 12:121
  43. Several studies have investigated the value of alpha-synuclein assay in the cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) patients in the differential diagnosis of t...

    Authors: Olivier Bousiges, Nathalie Philippi, Thomas Lavaux, Armand Perret-Liaudet, Ingolf Lachmann, Caroline Schaeffer-Agalède, Pierre Anthony, Anne Botzung, Lucie Rauch, Barbara Jung, Paulo Loureiro de Sousa, Catherine Demuynck, Catherine Martin-Hunyadi, Benjamin Cretin and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2020 12:120
  44. Here, we address a pivotal factor in Alzheimer’s prevention—identifying those at risk early, when dementia can still be avoided. Recent research highlights an accelerated forgetting phenotype as a risk factor ...

    Authors: Alfie R. Wearn, Esther Saunders-Jennings, Volkan Nurdal, Emma Hadley, Michael J. Knight, Margaret Newson, Risto A. Kauppinen and Elizabeth J. Coulthard
    Citation: Alzheimer's Research & Therapy 2020 12:119
  45. Blood-based biomarkers for Alzheimer’s disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the p...

    Authors: Inge M. W. Verberk, Elisabeth Thijssen, Jannet Koelewijn, Kimberley Mauroo, Jeroen Vanbrabant, Arno de Wilde, Marissa D. Zwan, Sander C. J. Verfaillie, Rik Ossenkoppele, Frederik Barkhof, Bart N. M. van Berckel, Philip Scheltens, Wiesje M. van der Flier, Erik Stoops, Hugo M. Vanderstichele and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2020 12:118
  46. The clinical guidelines related to the primary prevention of Alzheimer’s disease (AD) have focused on the management of vascular risk factors. However, the link between vascular risk factors and AD in older ad...

    Authors: Hyewon Lee, Kiwon Kim, Yeong Chan Lee, Soyeon Kim, Hong-Hee Won, Tae Yang Yu, Eun-Mi Lee, Jae Myeong Kang, Matthew Lewis, Doh Kwan Kim and Woojae Myung
    Citation: Alzheimer's Research & Therapy 2020 12:117
  47. Malnutrition is common in patients with Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) and is associated with institutionalization and increased mortality. Malnutrition is the result of ...

    Authors: Astrid S. Doorduijn, Marian A. E. de van der Schueren, Ondine van de Rest, Francisca A. de Leeuw, Heleen M. A. Hendriksen, Charlotte E. Teunissen, Philip Scheltens, Wiesje M. van der Flier and Marjolein Visser
    Citation: Alzheimer's Research & Therapy 2020 12:116